A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research

•dMMR mCRC patients have decreased chemosensitivity versus pMMR mCRC patients.•Different systemic non-immunotherapies show varying efficacy in dMMR mCRC patients.•Insufficient data exists to definitively conclude which systemic agent is preferred.•Meta-analysis of patient-level data may provide insight to guide optimal treatment.•To optimize dMMR treatment, more representative preclinical models are needed.